Congenital afibrinogenemia is a rare, inherited blood disorder in which the blood does not clot normally. It occurs when there is a lack (deficiency) of a protein called fibrinogen, which is needed for the blood to clot.
This rare disease is caused by an abnormal gene that must be passed down from both parents. It causes a severe lack of fibrinogen. (Dysfibrinogenemia, in which there is a defect in fibrinogen function, is a different condition.)
Congenital afibrinogenemia can occur in males or females. The main risk factor is a family history of bleeding disorders.
If the health care provider suspects a bleeding disorder, laboratory tests can determine the type and extent. This disorder usually shows up in childhood, often at birth.
- Clotting time
- Fibrinogen levels
- Partial thromboplastin time (PTT)
- Prothrombin time (PT)
- Reptilase time
- Thrombin time
All of these tests are abnormal in afibrinogenemia.
Excess bleeding is common with this condition. These episodes may be severe, or even fatal. Bleeding in the brain is a leading cause of death in patients with this disorder.
Call your health care provider or seek emergency care if you have excessive bleeding.
Tell your surgeon before you have surgery if you know or suspect you have a bleeding disorder.
- Bleeding from the umbilical cord
- Bleeding from the mucus membranes
- Bleeding in the brain (intracranial bleeding)
- Clotting with treatment
- Development of antibodies (inhibitors) to fibrinogen with treatment
To treat bleeding episodes or to prepare for surgery to treat other conditions, patients may receive:
- The liquid portion of the blood (plasma)
- A blood product containing concentrated fibrinogen (cryoprecipitate) through a vein (transfusion)
People with this condition should have the hepatitis B vaccine because transfusion increases the risk of hepatitis.
There is no known prevention. Couples who are thinking about having children may find genetic counseling helpful if at least one partner has this condition.
Kessler C. Hemorrhagic disorders: Coagulation factor deficiencies. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 180.
Review Date: 3/2/2009
Reviewed By: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2009 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.